Dear Friends,

It became apparent this year that all of us together are greater than bladder cancer. In fact, 2015 is best summarized as a breakthrough year. We doubled the number of patients reached through our programs and educational support services by empowering them with vital tools and information and embarked on the most promising research initiative in the Bladder Cancer Advocacy Network’s (BCAN) ten-year history.

Advocacy efforts are critical to our mission and BCAN volunteer advocates are uniquely positioned and trained to respond to a broad array of issues involving bladder cancer. This year we heightened our efforts to shape and influence federal legislation by visiting members of Congress during our Hill day. In 2015, we were successful in securing a Senate resolution declaring May as “National Bladder Cancer Awareness Month” and thanks to the tremendous efforts of our volunteer advocates, voices of the bladder cancer community were heard all over the country.

BCAN observed its ten-year anniversary with celebration and reflection. This milestone commemorated with a gala recognizing the many volunteers and donors that helped to shape the organization into what it is today and by looking forward to the promises of tomorrow.

With the ultimate goal to provide every patient with the opportunity to be an exceptional responder to personalized therapy, BCAN launched the Bladder Cancer Genomics Consortium (BCGC). A collaboration of eight leading academic medical institutions, BCGC’s first project is a large-scale genomics bladder cancer study.

Our 2015 successes are a testament to the visionary leadership of Co-Founder Diane Zipursky Quale, and we are honored to continue building on her legacy.

Finally, as we move into the world with more emphasis on bladder cancer and our mission to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community, we know that our progress is a result of the generosity of BCAN’s supporters and volunteers. We remain grateful for your passion and commitment to a world free from bladder cancer.

With great appreciation for your support,

Andrea Maddox-Smith
Chief Executive Officer

Gerald McNamara
Chair of the Board

The Bladder Cancer Think Tank collaborated in North Carolina.

May was declared “National Bladder Cancer Awareness Month.”

“BCAN TEN!” celebrated BCAN’s ten-year anniversary.

BCGC was launched, focusing on personalized medicine.
RESOLUTION

Expressing support for the designation of the month of May 2015, as “National Bladder Cancer Awareness Month”;

Whereas 500,000 families in the United States live with bladder cancer;

Whereas more than 74,000 people are expected to be diagnosed with bladder cancer and 16,000 will die due to the disease in 2015 alone;

Whereas bladder cancer affects people of all ages and backgrounds and is among the top 10 cancers with the highest incidence rates in the United States;

Whereas bladder cancer is known as one of the most expensive cancers to treat on a per patient basis with a recurrence rate of approximately 50 to 80 percent, requiring lifelong surveillance;

Whereas bladder cancer symptoms, such as blood in the urine, are easily recognized, however, many are unaware of the threat of bladder cancer, often prolonging the time to diagnosis;

Whereas if diagnosed early, bladder cancer is treatable;

Whereas military veterans are twice as likely as nonveterans to be diagnosed with bladder cancer;

Whereas women are often diagnosed at a later stage in the development of bladder cancer, and when diagnosed at the same stage as men, women have a worse prognosis;

Whereas if diagnosis and treatment are delayed, the life expectancy of an individual with bladder cancer decreases;

Whereas the quality of life of a person with bladder cancer will depend on future treatment and diagnosis developments, which will rely on research advancements;

Whereas there have been no new treatments approved by the Food and Drug Administration for bladder cancer in over 10 years;

Whereas research advancements for bladder cancer are limited by lack of awareness about the disease within the medical community and general public;

Whereas increased awareness will promote early diagnosis and increase the chances of survival;

Whereas increased awareness will bolster public support of the disease and thus increase funding for innovative research and the development of new treatment options and diagnostic tools;

Whereas traditionally on the first Saturday in May each year, survivors, caregivers, and loved ones walk together throughout the United States to raise awareness of bladder cancer;

Whereas the Bladder Cancer Advocacy Network and its community of patients, caregivers, and specialists seek—

(1) to foster a community of hope and support,

(2) to fund and conduct research for innovative treatments and diagnostic tools; and

(3) to increase public awareness and understanding of bladder cancer; and

Whereas May would be an appropriate month to designate as “National Bladder Cancer Awareness Month”: Now, therefore, be it.

Resolved, That the Senate—

(1) supports the designation of May 2015, as “National Bladder Cancer Awareness Month”;

(2) supports the goals and ideals of National Bladder Cancer Awareness Month; and

(3) calls on the people of the United States, interested groups, and affected persons—

(A) to promote awareness of bladder cancer and to foster understanding of the impact of the disease on patients and their families and caregivers;

(B) to take an active role in the fight to end bladder cancer; and

(C) to observe National Bladder Cancer Awareness Month with appropriate ceremonies and activities.
“BCAN TEN!” marked the celebration and reflection of our first decade, while inspiring future BCAN initiatives.
During the month of May, the bladder cancer community came together across the nation to raise awareness and funds.
Introducing an innovative collaboration between the Bladder Cancer Advocacy Network (BCAN) and major medical centers to develop an enriched understanding of the genomic profile of bladder cancer and facilitate the development of novel therapeutics. This $1.6 million investment through private philanthropy will increase collaborative research to improve outcomes for bladder cancer patients.

PRECISION MEDICINE IN BLADDER CANCER

The Cancer Genome Atlas (TCGA) results suggest potential therapeutic targets in 70% of bladder cancer tumors.

More than 32 genes have been identified as playing a critical role in bladder cancer biology.

Additional sequencing and sharing of data is needed to identify those molecular alterations that are most likely to be actionable and impacted by targeted treatments.

Pilot Project: UC-GENOME

Urothelial Cancer-GENOmic analysis to iMprove patient outcomes and rEsearch

Enroll 200 metastatic bladder cancer patients

Tumor tissue sent for Next Generation Sequencing (NGS) at no cost to patient or institution

Patients and their physicians receive a comprehensive report on potential treatments and clinical trials of novel therapeutics based on the genomic profile of their tumor

De-identified biospecimens and clinical information housed in a central biorepository and database for collaborative research opportunities

Study management provided by: Hoosier Cancer Research Network

Next Gen Sequencing provided by: Paradigm
At the annual Bladder Cancer Think Tank, participants focused on identifying obstacles and creating solutions in bladder cancer research, fostering discussions to help define priorities for advancing bladder cancer research.

BCAN Volunteers, Chapters, and Support Groups made every effort to ensure the bladder cancer community was represented and had a strong voice from coast to coast through advocacy, fundraisers, health and lunch fairs.

**BCAN Memorable Moments**
2015 Bladder Cancer Research Innovation Award Winner

JAMES FAMILY FOUNDATION AND PARTNER FUND MANAGEMENT BLADDER CANCER RESEARCH INNOVATION AWARD

Cory Abate-Shen, Ph.D.
Professor of Urological Oncology at Columbia University Medical Center and Associate Director of Translational Research at the Herbert Irving Comprehensive Cancer Center “Epigenetic regulation of bladder cancer progression.”

2015 Young Investigators

THE STEPHEN HALE GUSHÉE YOUNG INVESTIGATOR AWARD

Rahul Parikh, M.D., Ph.D.
University of Pittsburgh
“The Role of ATM Loss and the ATR-CHK1 Pathway in Bladder Cancer”

THE MIRIAM GLEBERMAN YOUNG INVESTIGATOR AWARD

Philip Palmbos, M.D., Ph.D.
University of Michigan
“The Role of TP63 and ATDC in Invasive Bladder Cancers”

2015 John Quale Travel Fellows

Abdul R. Banday, Ph.D., M.S.
National Cancer Institute
Max Kates, M.D.
Johns Hopkins Medical Institutions

Huyen T. Nguyen, Ph.D.
The Ohio State University
Randy Sweis, M.D.
University of Chicago
2015: The Year at a Glance

Income Growth

2015 Total = $3,575,438

Expense Composition

2015 Total = $2,061,030

Additional Highlights in 2015

BCAN launched the Survivor 2 Survivor program, connecting newly diagnosed patients with a volunteer survivor who provides their firsthand account of life with a bladder cancer diagnosis.

“The New Normal: Living with a Urinary Diversion” videos introduced eight bladder cancer survivors giving voice to their choice to let others know about living well with a urinary diversion.

The PCORI supported Patient Survey Network started with over 800 participants providing input on research questions that are important to bladder cancer patients.
Thank You to our Generous Donors

The following list includes individual donors who contributed $500 and higher between January 1, 2015 and December 31, 2015.
We appreciate the generosity of all of our supporters.

$100,000 - $249,000
Gerald McNamara and Renée Petrofes

$25,000 - $49,999
David Hoffman and Joan Sarnat
Joseph H. Gleberman

$10,000 - $24,999
Suzanne Andracki
Jordan and Kim Dickstein
The Estate of Marilyn Flynn Gushée
David and Carol Pulver
Andrew and Sally Quale
William U. Shipley, M.D., FACR and Jenise Shipley

$5,000 - $9,999
Anonymous
Antoinette Bush
Stephanie Greenberg
Mary C. Gushée
John Holmes
Andrea Kasarsky
Robert and Abby Levin
Fred and Marlene Malek
Jessica Newsome and Jane Pancheco
Diane Zipursky Quale
Mace Rosenstein and Louise de la Fuente
Bob and Pat Schieffer
Michael Sobel
Jeff Webb
K. David Weidner, Ph.D. and William Gannon, M.D.
Morley and Charlotte Zipursky

$1,000 - $4,999
Wick Allison
Lamberto Andreotti
Shawn Anglum
Anonymous
Henri Bagdahdi
Rick Bangs
Martin Baucom
Carolyn Bechtel
Ambaw Bellette
James Bondi
Brooksley Born
Earle Burgess
Rachel Camarena
Tressa Caldwell
Tom Campbell
Cheryl Chiuchiarelli
Cheryl Coviello
Susan Donahue
Thomas and Cindy Duffy
Beth Fascitelli
Barbara J. Field
Joyce C. Fisher
Joseph P. Flanagan
Samantha Francesca
Ken Gertz
Bart Gohmann
Marlys Gramley
Thomas Green
Erika R. Greenfield
David Grossman
Lauryn Guttenplan
Cynthia Hardie
Mark Himelstein
Nancy E. Hogan
Mary Hulitar
Steve Johnson

Elaine Johnston
Julianna Kasper
Bobbie Kern
Rony and Ana Kessler
Sue Kolaga
Cheryl Taylore Lee, M.D.
Seth Lerner, M.D. and Karen Lerner
Peter Lipman
Robert Lipman
Marlene A. Malek
Stephen McCourt
Edward G. McDougall
Andrew Mohr
Natasha Moore
William Moroney
Jim and Ellen Myerberg
Mike Nash
Kelly Nash
E. R. Newman
Michael Panzara
Lawrence Patrick
Kathryn Patton
Wally Podbielski
Brian D. Pokropski
Carol Pullman
Mark and Teresa Quale
Mary Eleanor Roberts
Mike Salvino
Martin Sarver
Ronald Saunders
David Schlee
Mark P. Schoenberg
James Screeden
Jo Ann Sears
Jared Sher
Neal Shore
Robert N. Steckler

Bladder Cancer Advocacy Network  ●  4915 St. Elmo Avenue, Suite 202, Bethesda, M.D. 20814  ●  1-888-901-BCAN  ●  WWW.BCAN.ORG

10
Thank You to our Generous Donors

The following list includes individual donors who contributed $500 and higher between January 1, 2015 and December 31, 2015.
We appreciate the generosity of all of our supporters.

$1,000 - $4,999 (continued)

Gary Steinberg, M.D.
William Steingrandt
Malcolm Tuesley
Jacqueline Vanier
Kevin Watson
Carol Weida
Erica Wolfe
Karrie Wright
Alisa Zipursky
Richard E. Zoyhofski

$500 - $999

Jodi Aase
Joseph Alexander
Bonita Allinder
Cynthia Anderson
Tony Angiuli
Steve Arnold
Christopher Ausobsky
Kelly Austin
Sam Awotwi
Ann Barth
James Bayes
Kim Beaudoin
Robert Beizer
Cynthia Berg
Kevin Brady
Nathaniel Brown
Gregory Brown
Henry Bulifant
Michael Burton
Nina Butler
Sara Call
Denis Campbell
Viresh Chana
Connie Chesser
Lucinda Cloutier
David Cohen
Gabrielle Conklin
Elena Cox
Daria De Piro
George S. Dembroski
Marianne DePippo
Joseph DeTommaso
Thomas Dillon
Robert M. Dolman
Ronald L. Douglas
Barbara Edelin
Harriette Evans
Gary Falcone
David Farber
Kurt J. Faxon
Paul Fayad
Nancy Fitzgibbons
Fred Fletcher
Marvin and Cookie Friedman
Claudia Galbo
Tullika Garg
Tom Gephardt
Bridget Gibson
John Giegerich
Jamie and Andrea Gillespie
John Giuiano
Michael M. Goldstein
Helen B. Gray
Dennis Greenwald
Susan G. Guttmann
Sharon Hagen
John H. Haire
Laurie Harvey
Roslyn Hees
Harry Herr
Ira Hersh
Jean Hoffman-Censtis, M.D.
John Hren
Beata Jachulski Baker
David Jedd
Curtis A. Johnson
Meredith Jones
Dean Junkans
Christina Jurik
Adam Jurik
Larry Karsh
John Keogh
Renata Khoshroo
Mary King
Laurence Klurfeld
Diana Kolaitis
Lewis Kramer
Neil Kurtz
Ben Lavon
Jane Lee
Don Levens
Donald Litke
Ron Madison
Linda Magram
Carol Martin
Erik Martin
Edmund McAlister
Iris H. Medvid
Lynn Miller
Karen Millward
Ed Murphy
Charlotte D. Nau
Henry Neuberger
Wayne Norbitz
Jay and Lisa O’Donnell
The following list includes individual donors who contributed $500 and higher between January 1, 2015 and December 31, 2015. We appreciate the generosity of all of our supporters.

<table>
<thead>
<tr>
<th>$500 - $999 (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Parker</td>
</tr>
<tr>
<td>Rakesh Patel</td>
</tr>
<tr>
<td>Elizabeth Patterson</td>
</tr>
<tr>
<td>Jennifer Pietenpol</td>
</tr>
<tr>
<td>Betsy Plimack</td>
</tr>
<tr>
<td>Barbara Powell</td>
</tr>
<tr>
<td>Melissa Price</td>
</tr>
<tr>
<td>Thomas W. Queen</td>
</tr>
<tr>
<td>Laura T. Renshaw</td>
</tr>
<tr>
<td>Howard F. Robins</td>
</tr>
<tr>
<td>Cynthia Rossetti</td>
</tr>
<tr>
<td>Stefanie Roth</td>
</tr>
<tr>
<td>Carol Ruffo</td>
</tr>
<tr>
<td>Susan Sajadi</td>
</tr>
<tr>
<td>Jennifer L. Sale</td>
</tr>
<tr>
<td>Mark Sank</td>
</tr>
<tr>
<td>Kenneth I. Schaner</td>
</tr>
<tr>
<td>Paul Schreiber</td>
</tr>
<tr>
<td>David Schulman</td>
</tr>
<tr>
<td>Jenna Scriverano</td>
</tr>
<tr>
<td>Brenda K. Segall</td>
</tr>
<tr>
<td>Frank Sharp</td>
</tr>
<tr>
<td>John Sherbin</td>
</tr>
<tr>
<td>Larry Sidman</td>
</tr>
<tr>
<td>Timothy Smith</td>
</tr>
<tr>
<td>Mark S. Soloway</td>
</tr>
</tbody>
</table>
# Thank You to our Generous Corporations, Foundations, and Organizations

The following list includes corporations, foundations, and organizations who contributed $500 and higher between January 1, 2015 and December 31, 2015.

<table>
<thead>
<tr>
<th>Tier</th>
<th>Amount Range</th>
<th>Organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$250,000 +</td>
<td>The James Family Foundation</td>
</tr>
</tbody>
</table>
|     | $100,000 - $249,000 | Genentech, Inc.  
*a member of Roche Group*  
The JPB Foundation |
|     | $50,000 - $99,000 | Merck  
Photocure |
|     | $25,000 - $49,999 | Bristol-Myers Squibb Foundation  
Eli Lilly and Company  
Endo Pharmaceuticals  
Karl Storz Endoscopy-America, Inc.  
Olympus  
OncoGenex Technologies, Inc.  
Onyx Pharmaceuticals, Inc. |
|     | $10,000 - $24,999 | Abbott Molecular  
The Ashley Family Foundation, Inc.  
The Dana Foundation  
Direct TV Inc.  
Heat Biologics, Inc  
IOS Press  
National Association of Broadcasters  
Pacific Edge Diagnostics  
PhrMA  
Taris Biomedical, LLC  
Telesta Therapeutics  
TheraCoat Ltd. (now UroGen Pharma)  
Viventia Bio, Inc.  
The Urological Institute of Northeastern New York  
University of Michigan Comprehensive Cancer Center  
Silicon Valley Community Foundation |
|     | $5,000 - $9,999 | University of Colorado Cancer  
Mildred Hoit, Inc.  
Local Independent Charities Of America (LICA)  
The Mount Sinai School of Medicine  
AXA Art Americas Corporation  
Beallsville Sportsmans Club  
Bravelets, LLC  
Cohen Mohr LLP  
Dorfman Mizrach & Thaler, LLP  
Evelyn and Arthur, Inc.  
Greater Lehigh Valley WOCN  
Houghton Mifflin  
Metro Bowhunters Resource Base Inc.  
Michigan Institute of Urology, P.C.  
Monetta Group  
North Alabama Urology, P.C.  
Perkins Coie Foundation  
Pioneer Linens  
Scanport, Inc.  
The Edward and Lucille Kimmel Foundation, Inc.  
The Urology Group  
Wiley Rein LLP |
|     | $1,000 - $4,999 | 21st Century Fox America, Inc.  
Albany Medical Center  
Blackburn & Company Incorporated  
Central Nassau County/Rotary Foundation Inc.  
Enterprise Holdings, Inc.  
Fine Mark National Bank Trust  
Illinois Shotokan Booster Club  
Inspire/ClinicaHealth Inc.  
J. McLaughlin  
The J.M. Rubin Foundation  
JPA Health Communications  
LMCG Investments, LLC  
Marcy and Leona Chanin Foundation, Inc.  
Maryland Charity Campaign  
MD Anderson Cancer Center  
The Benevity Community Impact Fund  
Melva Bucksbaum Family Foundation  
BCAN NC Triangle Chapter  
Pace Family Trust  
Redstone Federal Credit Union  
Ritchers of Palm Beach  
Rush Enterprises, Inc.  
Small Army for a Cause, Inc.  
The Lagomarsino Foundation  
The Margolis Foundation, Inc.  
The Thompson Group at Morgan Stanley  
Tuality - OHSU Cancer Center |
Board of Directors

Gerald C. McNamara, Chair of the Board
Diane Zipursky Quale, Co-Founder
Robert Levin, Treasurer
Jared Sher, Secretary
Beverly James
Cheryl T. Lee, M.D.
Seth Lerner, M.D., FACS
David Pulver
Mace Rosenstein
William U. Shipley, M.D., FACS

Scientific Advisory Board

Gary D. Steinberg, M.D., FACS, Chairperson
University of Chicago

Hikmat Al-Ahmadie, M.D.
Memorial Sloan-Kettering Cancer Center

Andrea Apolo, M.D.
National Cancer Institute
Jessie Au, PharmD., Ph.D.
Optimum Therapeutics
Dean F. Bajorin, M.D.
Memorial Sloan-Kettering Cancer Center

Bernard Bochner, M.D.
Memorial Sloan-Kettering Cancer Center
Sam Chang, M.D.
Vanderbilt University School of Medicine

Michael Cookson M.D.
University of Oklahoma College of Medicine
Guido Dalbagni, M.D., FACS
Memorial Sloan-Kettering Cancer Center
Sia Daneshmand, M.D.
USC/Norris Comprehensive Cancer Center
Colin P.N. Dinney, M.D.
MD Anderson Cancer Center

Robert Dreicer M.D., MS
University of Virginia

Michael Droller, M.D.
Mount Sinai Medical Center

Mario L. Eisenberger, M.D.
Johns Hopkins Medical Institutions

Matthew Galsky, M.D.
Mount Sinai School of Medicine
Scott M. Gilbert, M.D., MS
Moffitt Cancer Center
Mark L. Gonzaligo, M.D., Ph.D.
University of Miami
H. Barton Grossman, M.D., FACS
MD Anderson Cancer Center
Noah M. Hahn, M.D.
Johns Hopkins Medical Institutions
Donna Hansel, M.D., Ph.D.
University of California, San Diego
J. Stephen Jones, M.D., FACS
Glickman Urological and Kidney Institute
Cleveland Clinic
Ashish M. Kamat, M.D.
MD Anderson Cancer Center
Larry Karsh, M.D., FACS, CPI
The Urology Center of Colorado
Wassim Kassouf, M.D.
McGill University
Badrinath Konety, M.D., FACS, MBA
University of Minnesota
Donald Lamm, M.D., FACS
BCG Oncology
David M. Latini, Ph.D.
Baylor College of Medicine
Cheryl Lee, M.D., FACS
University of Michigan
Seth Lerner, M.D., FACS
Baylor College of Medicine
Yair Lotan, M.D.
UT Southwestern Medical Center

Kevin Loughlin, M.D., MBA, FACS
Brigham & Women’s Hospital
S. Bruce Malkowicz, M.D.
University of Pennsylvania

David J. McConkey, M.D., Ph.D.
MD Anderson Cancer Center
James McKiernan, M.D.
Columbia University
Edward M. Messing, M.D., FACS
University of Rochester Medical Center

Staff *Updated as of 2016

Andrea Maddox-Smith, Chief Executive Officer
Stephanie Chisolm, PhD, Director of Education and Research
Anita Parker, Director of Development
Alejandra Spangler, Education and Research Manager
Trenny Stephens, Office Manager
Rebecca Yannopoulus, Walk Manager

BCRN Management Committee

Hikmat Al-Ahmadie, M.D.
Memorial Sloan-Kettering Cancer Center
Jessie Au, PharmD., PhD
Optimum Therapeutics
Dean F. Bajorin, M.D.
Memorial Sloan-Kettering Cancer Center
Robert Dreicer M.D., MS
University of Virginia
David M. Latini, PhD
Baylor College of Medicine
Seth Lerner, M.D., FACS
Baylor College of Medicine
Yair Lotan, M.D.
UT Southwestern Medical Center
David J. McConkey, M.D., PhD.
MD Anderson Cancer Center
Scientific Advisory Board (continued)

Matthew I. Milowsky, M.D.
UNC Lineberger Comprehensive Cancer Center

Matthew Nielsen, M.D.
University of North Carolina at Chapel Hill

Michael O’Donnell, M.D., FACS
Holden Cancer Center, University of Iowa Hospital

Michael Porter, M.D., MS
University of Washington

Raj S. Pruthi, M.D., FACS
University of North Carolina at Chapel Hill

Jonathan E. Rosenberg, M.D.
Memorial Sloan-Kettering Cancer Center

Arthur I. Sagalowsky, M.D.
UT Southwestern Medical Center

Mark Schoenberg, M.D., FACS
Albert Einstein College of Medicine

Shahrokh F. Shariat, M.D.
Medical University of Vienna

William U. Shipley, M.D., FACR
Harvard Medical School and Massachusetts General Hospital

Neal D. Shore, M.D., FACS
Carolina Urologic Research Center

Eila Skinner, M.D.
Stanford University

Norm D. Smith, M.D.
The University of Chicago

Mark Soloway, M.D., FACS
Memorial Healthcare System

Srikantha Sridhar, M.D.
Princess Margaret Hospital

Walter Stadler, M.D.
University of Chicago

John A. Taylor, III, M.D., MS
University of Connecticut Health Center

Dan Theodorescu, M.D., Ph.D.
University of Colorado Cancer Center

Steve Wong, M.D.
University of California Los Angeles

Leadership Council

Carol Auerbach
Rosie Bartolotta
Nona Bear
Ambaw Bellete
Jordan Dickstein
Gary Forman
Stacy Robinson Fuller
Mary Gushee
Cynthia Hardie
Calvin Hicks
Christine Keogh Stone
Ella Kot
Simon Lemmy
Ron Stein
K. David Wiedner, Ph.D.

BCAN Chapters

Albany
Denise DiMascio, President

Dallas-Forth Worth
Anthony Brewer, President

Greater Omaha
Jeff Henrichsen, President

Lehigh Valley/Central PA
Marge Coffin, President

NC Triangle
David Langham, President

New Jersey
Mary Ann Aregood, Co-President
Dana Caparoso, Co-President

Stay Connected

For the latest BCAN news and bladder cancer information, join us on social media.

@B_C_A_N

Facebook.com/BladderCancer

@B_C_A_N

Inspire.com/groups/bladder-cancer-advocacy-network